NuCana (NCNA) Other Non-Current Liabilities (2017 - 2025)

NuCana (NCNA) reported Other Non-Current Liabilities of $77149.6 for Q4 2025, up 50.27% on a YoY basis from $51340.1 in Q4 2024, and down 1.42% sequentially from $78263.0 in Q3 2025.

NuCana (NCNA) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends

NuCana (NCNA) has 9 years of Other Non-Current Liabilities data on file, last reported at $77149.6 in Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 50.27% year-over-year to $77149.6; the trailing twelve-month figure through Dec 2025 stood at $77149.6 (up 50.27% YoY), and the FY2025 full-year result was $76473.6, up 49.56% from the prior year.
  • Other Non-Current Liabilities declined to $77149.6 in Q4 2025, from $78263.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 million in Q1 2023 to a low of $38979.0 in Q3 2024.
  • A 5-year average of $729175.5 and a median of $68141.2 in 2023 frame the typical range for Other Non-Current Liabilities.
  • Across the five-year window, Other Non-Current Liabilities jumped 7883.35% in 2023 and slumped 98.51% in 2024, its largest moves.
  • Tracing NCNA's Other Non-Current Liabilities over 5 years: stood at $62008.5 in 2021, then jumped by 7655.4% to $4.8 million in 2022, then slumped by 98.5% to $71986.8 in 2023, then decreased by 28.68% to $51340.1 in 2024, then jumped by 50.27% to $77149.6 in 2025.
  • Business Quant data shows NCNA's Other Non-Current Liabilities at $77149.6 in Q4 2025, $78263.0 in Q3 2025, and $77374.6 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 77,149.64
Sep 30, 2025 78,263.00
Jun 30, 2025 77,374.65
Mar 31, 2025 50,380.02
Dec 31, 2024 51,340.07
Sep 30, 2024 38,979.00
Jun 30, 2024 73,208.80
Mar 31, 2024 73,574.05
Dec 31, 2023 71,986.81
Sep 30, 2023 73,467.72
Jun 30, 2023 3.75 Mn
Mar 31, 2023 4.93 Mn
Dec 31, 2022 4.81 Mn
Sep 30, 2022 54,213.22
Jun 30, 2022 57,928.45
Mar 31, 2022 61,724.44
Dec 31, 2021 62,008.49
Sep 30, 2021 63,414.83
Jun 30, 2021 64,295.50
Mar 31, 2021 63,430.36